Finch Therapeutics Group, Inc. (FNCHQ)

Overview

Finch Therapeutics Group, Inc. stands as a pioneering clinical-stage microbiome therapeutics company engaged in the development of a new class of orally administered biological drugs within the United States. Established in 2014 and headquartered in Somerville, Massachusetts, Finch Therapeutics aims to harness the therapeutic potential of the human microbiome to treat various conditions. Through strategic collaboration and license agreements with esteemed entities like Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota, the company is at the forefront of translating microbial insights into clinically meaningful outcomes.

Products and Services

Finch Therapeutics Group, Inc. is developing a range of innovative microbiome product candidates, each designed to address specific medical conditions by leveraging the complex interactions within the human microbiome. Their product pipeline includes:

• FIN-211: Developed as a potential treatment for autism spectrum disorder (ASD), FIN-211 targets the gastrointestinal and behavioral symptoms associated with ASD by modulating the gut-brain axis through the microbiome. This candidate represents a novel approach to mitigating some of the core and associated symptoms of ASD by addressing the underlying microbial imbalances.
• FIN-524 and FIN-525: These product candidates are part of Finch Therapeutics' efforts to tackle inflammatory bowel disease (IBD), a term that encompasses conditions characterized by chronic inflammation of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis. By aiming to restore the natural balance of the gut microbiome, FIN-524 and FIN-525 offer a promising direction for the treatment of IBD, potentially reducing inflammation and improving patient quality of life.